Sinopharm vaccine(Ain Shams University)(Sinopharm vaccine(Ain Shams University))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

新型冠状病毒感染

原研机构

Ain Shams University

在研机构-

非在研机构

Ain Shams University

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 Sinopharm vaccine(Ain Shams University) 相关的临床试验

IRCT20131221015878N4

/ RecruitingN/AIIT

Immunogenicity and safety of pastocovac vaccine as a booster dose in comparison with sinopharm and pastocovac Plus boosters in Iranian adults aged 18 to 80 who received 2 doses of Sinopharm vaccine: a parallel group clinical trial

开始日期2022-02-26

申办/合作机构-

IRCT20201214049709N4

/ RecruitingN/AIIT

Comparison of immunogenicity and safety of Razi Cov Pars and Sinopharm booster doses in adults 18 years of age and older who have primarily vaccinated with Sinopharm: a ?parallel ??2?? arms, ?randomised, double blind clinical trial ?

开始日期2021-11-30

申办/合作机构

Razi Vaccine & Serum Research Institute

TCTR20210920005

/ Recruiting临床2期IIT

Immunogenicity and safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in adolescent (age 12-17 years) in Thailand.

开始日期2021-09-14

申办/合作机构-

100 项与 Sinopharm vaccine(Ain Shams University) 相关的临床结果

登录后查看更多信息

100 项与 Sinopharm vaccine(Ain Shams University) 相关的转化医学

登录后查看更多信息

100 项与 Sinopharm vaccine(Ain Shams University) 相关的专利（医药）

登录后查看更多信息

181

项与 Sinopharm vaccine(Ain Shams University) 相关的文献（医药）

2024-11-01·BMJ Open

Evaluation of BBIBP-CorV Sinopharm COVID-19 vaccine effectiveness in Sri Lanka: a test-negative case control study

Article

作者: Rathnayake, Kanchana ; Senaratne, Sumudu ; Premaratna, Ranjan ; Kosinna, Gihan ; Gunasena, Prasanna ; Weerarathna, Inosha ; Wimalasena, Wathsala ; Bogoda, Gayan ; De Silva, Shamila Thivanshi ; Kariyawasam, Manjula ; Ediriweera, Dileepa Senajith

ObjectivesThere is limited research on real-world effectiveness of BBIBP-CorV Sinopharm COVID-19 vaccine. This study evaluated real-world effectiveness of Sinopharm vaccine in Sri Lanka by assessing absolute vaccine efficacy.Design and settingA retrospective test-negative case-control study was conducted at ten large government hospitals across the country.ParticipantsConsecutive adults aged ≥18 years attending outpatient departments who tested reverse-transcription-PCR positive for SARS-CoV-2 during the study period were recruited.Main outcome measuresAn interviewer-administered questionnaire was administered, and outcome of COVID-19 infection was assessed in cases.ResultsOf 1829 recruited, 914 (49.9%) were male, and mean age was 45.2 (SD 15.3) years; 1634 (89.3%) were vaccinated with two doses of BBIBP-CorV Sinopharm vaccine, while 195 (10.1%) were vaccine-naïve. Compared with the vaccinated, unvaccinated persons were older but otherwise similar in their demographic and medical profiles. Unvaccinated were more likely to have fever, shortness of breath and vomiting as symptoms and were more likely to seek treatment. Significantly more vaccinated individuals received treatment at home. After admission, the unvaccinated were more likely to receive oxygen. Significantly more unvaccinated persons died of COVID-19 compared with the vaccinated. Sinopharm vaccine was 78.2% (94% CI 69.0% to 85.0%) effective at preventing COVID-19 infection, 88.7% (81.6%–93.2%) effective at preventing severe infection and 85.6% (69.6%–93.6%) effective at preventing death.ConclusionsBBIBP-CorV Sinopharm vaccine is effective at mitigating severity of illness and reducing the likelihood of hospitalisation, severe illness and death, in those who received primary vaccination, compared with the unvaccinated.

2024-11-01·Heliyon

Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety

Article

作者: Razaz, Seyad Hossein ; Mokarram, Ali Rezaei ; Sadeghi, Fariba ; Es-haghi, Ali ; Solaymani-Dodaran, Masoud ; Malek, Esmat ; Es-Haghi, Ali ; Moradi, Monireh Haji ; Kalantari, Saeed ; Hajimoradi, Monireh ; Mokhberalsafa, Ladan ; Fallah Mehrabadi, Mohammad Hossein ; Mokaram, Ali Rezae ; Banihashemi, Seyed Reza ; Nofeli, Mojtaba

IntroductionHeterologous vaccines enhance the immune response to new variants and allow flexibility in booster administration when the original vaccine is unavailable. Studies show that heterologous boosters can generate comparable or superior antibody responses compared to homologous boosters. Considering rare side effects is essential in evaluating COVID-19 vaccines, especially those associated with ChAdOx1-S (AstraZeneca) and Ad26.COV2.S (Janssen), including blood clotting and idiopathic thrombocytopenia. Severe side effects, such as myocarditis and pericarditis, may occur after Pfizer or Moderna boosters but are rare.MethodsThis study administered two vaccines: the Sinopharm inactivated virus vaccine and the Razi-CoV-Pars (RCP) booster. Various evaluations included biochemical markers, coagulation factors, autoimmune antibodies, and antibodies against concerning variants.ResultsAll 90 participants exhibited a notable rise in antibody levels against the variant of concern (VOC). Participants receiving the Razi-CoV-Pars booster after Sinopharm/BBIBP-CorV showed significantly higher antibody levels (Wuhan ∼ 3.25 times, Delta ∼4 times, Omicron ∼ 14 times) compared to those receiving Sinopharm's homologous vaccine. No significant changes (P: <0.05) were found in LDH, CPK, CK-MB, ANA, and Anti-CCP levels. However, individuals receiving Sinopharm's booster after two doses showed a significant increase (4 cases) in D-Dimer levels.ConclusionThe Razi-CoV-Pars vaccine demonstrates a favorable safety profile and promising potential as an effective booster against current variants, particularly due to its significant protective titer against Omicron.

2024-11-01·Human Antibodies

Evaluation of SARS-Cov-2 neutralizing antibody among Sinopharm Vero Cell (BBIBP-CorV) vaccinated medical students

Article

作者: Khadka, Sony ; Pradhan, Shanti ; Karn, Mitesh ; Subedi, Nuwadatta ; Shrestha, Prabin ; Poudel, Arjun ; Regmi, Sanjib Mani ; Bhandari, Dhaka Ram

BACKGROUND: Information regarding seropositivity and vaccine efficacy among medical students is scarce. This study aims to detect the status of SARS-CoV-2 neutralizing antibodies among the Sinopharm’s Vero Cell (BBIBP-CorV) vaccinated medical students. MATERIALS AND METHODS: A prospective, cross-sectional study was carried out among medical students of Gandaki Medical College Teaching Hospital, Pokhara, Nepal from March through August 2022. The level of SARS-CoV-2 serum- neutralizing IgG antibody was measured and its relation with participants’ age and sex, duration of vaccination, and any comorbid condition was determined. RESULTS: A total of 110 medical students were included in the final analysis, the majority being females (65.5%) and the mean age is 23.1 [Formula: see text] 3.2 years. Most of the students (96.4%) had neutralizing antibodies against SARS-CoV-2. Among the 29 (26.36%) students who received a booster dose, the positivity rate was 100%. The mean IgG levels were 9.57 [Formula: see text] 9.58 [Formula: see text]g/ml and 2.91 [Formula: see text] 2.47 [Formula: see text]g/ml among students receiving an additional booster dose and among those not receiving it, respectively. In the cohort receiving a booster dose of the vaccine, the average value of neutralizing IgG antibodies was high. In contrast, the ones not receiving it, the titers were low and showed a declining trend. CONCLUSION: Though the dose strategy of the Sinopharm vaccine is effective, booster vaccination may be an important strategy to ensure protection among medical students, who are at high risk of COVID-19 due to constant patient exposure during their training. Further studies should assess vaccine efficacy among individuals who received other vaccines as well.

100 项与 Sinopharm vaccine(Ain Shams University) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	埃及	Ain Shams University	2021-02-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISTH2022	N/A	凝血障碍	93	Sinopharm covid-19 Vaccine	築憲廠鹽衊築壓觸蓋選(繭膚獵鬱壓鑰築遞簾醖) = 蓋鏇襯衊糧鬱鬱積鬱鹹鏇齋膚範積膚齋積鹽鹽 (選夢網夢簾簾鹹憲窪顧 )	-	2022-07-09
EHA2022	N/A	血红蛋白病	434	Sinopharm vaccine	選夢願壓遞繭窪憲衊鏇(繭襯鬱蓋憲簾齋廠鏇積) = 鑰蓋廠齋蓋繭鬱醖窪廠遞鏇齋網艱鏇觸繭壓繭 (齋餘壓繭蓋積觸遞齋壓 ) 更多	-	2022-06-10
ASCO2022	N/A	肿瘤	177	Pfizer-BioNTech vaccine	窪選積齋範觸構選襯遞(遞壓網艱構繭襯積遞鏇) = 23 patients (13%) had confirmed COVID-19 infection (post AstraZeneca 1, Pfizer 13, Sinopharm 8, Sinovac 1) 膚繭膚願獵選襯餘獵憲 (鹽窪窪夢願範壓製遞壓 ) 更多	积极	2022-06-02
ASCO2022	N/A	肿瘤	177	Sinopharm (Beijing) vaccine		积极	2022-06-02